Drug Sponsors

Coronado Biosciences, City of Hope form Mustang Therapeutics

Friday, March 20, 2015 02:03 PM

Coronado Biosciences has formed a new company, Mustang Therapeutics, in partnership with California research and treatment center City of Hope. Mustang initially will focus on the preclinical and clinical development, as well as commercialization of proprietary Chimeric Antigen Receptor (CAR-T) technology. The deal is valued in excess of $40 million for the development of these CAR-T cells via up-front and milestone payments to City of Hope. It is anticipated the first two CAR-T cells from this partnership will begin enrollment in human clinical trials at the City of Hope this year.

More... »


Certara opens larger corporate headquarters in New Jersey

Thursday, March 19, 2015 12:10 PM

Certara, a global biosimulation technology-enabled drug development and drug safety consulting company, is moving its corporate headquarters to a larger location in Princeton, N.J.

More... »


Valeant Pharmaceuticals counterbids Endo, offers Salix $1.45B

Wednesday, March 18, 2015 01:25 PM

Valeant Pharmaceuticals International and Salix Pharmaceuticals have entered into an amendment to their Agreement and Plan of Merger, dated Feb. 20. Valeant increased the offer price to acquire all the outstanding common stock of Salix from $158 per share to $199 per share, for aggregate gross proceeds of approximately $1.45 billion.

More... »

Kite Pharma acquires T-Cell Factory for $21M

Wednesday, March 18, 2015 01:14 PM

Kite Pharma, a Santa Monica, Calif.-based, clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products based on CAR and TCR gene therapy platforms for the treatment of cancer, acquired T-Cell Factory (TCF), a privately held Dutch company, which has been renamed Kite Pharma E.U.

More... »

New immunotechnology center MI-mAbs launched

Monday, March 16, 2015 01:48 PM

MI-mAbs, a new immunotechnology center designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory disease and founding member of the France-based Marseille Immunopole (MI) cluster, has announced the signature of the consortium agreement sealing the commitment of its founders: Aix-Marseille Universite (AMU) and its private subsidiary Protisvalor, CNRS, Inserm, the Institute Paoli-Calmettes (IPC); three of their research centers (the Centre d'Immunologie de Marseille-Luminy, the Cancer Research Center of Marseille and the Center for Immunophenomics); Innate Pharma, a European immuno-oncology company; and Sanofi.

More... »

Ruthigen, Pulmatrix ink merger agreement

Monday, March 16, 2015 01:41 PM

Ruthigen, a biopharmaceutical company based in Santa Rosa, Calif., and Pulmatrix, a Lexington, Mass.-based clinical stage biotech, have entered into a definitive merger agreement. Pulmatrix will become a wholly-owned subsidiary of Ruthigen and all of Pulmatrix's debt and equity securities outstanding prior to the consummation of the merger will be exchanged for shares of Ruthigen common stock that will represent approximately 81% of the outstanding common stock of Ruthigen.

More... »

Par Pharmaceutical files for IPO

Friday, March 13, 2015 12:55 PM

Par Pharmaceutical Holdings has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered by Par Pharmaceutical and its shareholders, and the price range for the offering, have not yet been determined.

More... »

Ember, Mariel Therapeutics ink merger agreement

Friday, March 13, 2015 12:33 PM

Ember Therapeutics, a Boston-based biotech discovering and developing novel obesity and diabetic related therapies, will merge with Mariel Therapeutics, a privately held, New York-based biotech developing targeted therapies for osteoarthritis and kidney fibrosis using Bone Morphogenetic Protein (BMP)-7.

More... »

GSK establishes Asian global headquarters in Singapore

Thursday, March 12, 2015 01:00 PM

GlaxoSmithKline is strengthening its presence in Singapore by establishing a new global headquarters for Asia, further expanding its commitment to patients and consumers in the region.

More... »

Endo bids to acquire Salix for $11 billion

Thursday, March 12, 2015 12:58 PM

Raleigh, N.C.-based Salix Pharmaceuticals has received an unsolicited proposal from Endo International, a global specialty healthcare company headquartered in Dublin, Ireland, to acquire all outstanding shares of common stock of the company for a combination of 1.4607 shares of Endo common stock and $45 cash per share of common stock. Based on the closing stock price of Endo on March 10, 2015, the transaction is valued at $175 per Salix share. 

More... »

CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs